Anuh Pharma (506260) Q1 24/25 earnings summary

Executive summary

• Revenue from operations for Q1 FY25 was ₹13,790.83 lakhs, down from ₹16,148.06 lakhs year-over-year and ₹16,389.07 lakhs sequentially.

• Profit after tax for the quarter was ₹950.91 lakhs, compared to ₹1,175.28 lakhs in Q1 FY24 and ₹1,535.82 lakhs in Q4 FY24.

• Financial results were reviewed by the Audit Committee and approved by the Board on August 9, 2024.

Financial highlights

• Total revenue for Q1 FY25 was ₹14,162.74 lakhs, compared to ₹16,495.03 lakhs in Q1 FY24.

• EBITDA for Q1 FY25 was ₹1,428.81 lakhs (EBITDA margin 10.36%), down from ₹1,744.49 lakhs (10.80%) in Q1 FY24.

• Adjusted EBITDA (excluding forex and MTM gains/losses) was ₹1,250.86 lakhs (margin 9.07%) versus ₹1,472.62 lakhs (9.12%) in Q1 FY24.

• Basic and diluted EPS for Q1 FY25 stood at ₹1.90, compared to ₹2.35 in Q1 FY24.

Outlook and guidance

• No forward-looking guidance or outlook was provided.